^
9ms
The potential of EZH2 expression to facilitate treatment choice in stage II colorectal adenocarcinoma. (PubMed, Histol Histopathol)
The OS of stage II CRC with high EZH2 expression improved more strikingly with surgery and adjuvant chemotherapy than with surgery alone, which suggests the potential of EZH2 expression as a biomarker to help identify a subgroup of early-stage CRC benefiting from surgery and adjuvant chemotherapy. More large-scale studies are warranted to corroborate this finding and to further evaluate the predictive nature of EZH2.
Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
|
EZH2 underexpression
almost2years
Clinical implication of EZH2 inhibitors in hepatocellular carcinoma (AACR 2023)
We aim to uncover a novel mechanism for EZH2-mediated resistance to ferroptosis in HCC. Multi-step analyses were performed with genomic data from mouse models (Ezh1/2 KO), cancer cell lines treated with EZH2i GSK126, and primary tumors including HCC to identify genetic networks or signaling/metabolic pathways associated with EZH2 in cancer cells. EZH2 is a novel suppressor of ferroptosis by negatively regulating lipid metabolism. Thus, our study provides scientific evidence for developing a novel therapeutic strategy for treatment of HCC patients with co-treatment of ferroptosis inducers and EZH2 inhibitors.
Clinical
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
|
EZH2 underexpression
|
GSK2816126 • erastin
almost2years
Expression of Enhancer of Zeste Homolog 2 (EZH2) Gene in Acute Myeloid Leukemia. (PubMed, Asian Pac J Cancer Prev)
Low EZH2 expression is prevalent in Egyptian AML patients subsequently; it is suggested to function as tumor suppressor gene rather than an oncogene. Moreover, EZH2 downregulation is associated with resistance to chemotherapy and high mortality rate.
Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
|
EZH2 underexpression
2years
EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico Analysis. (PubMed, Biomolecules)
Finally, we inferred that immunotherapy may be more effective for PCa patients with low EZH2 expression. In conclusion, our study showed that EZH2 could be a potentially efficient predictor of prognosis and immune response in PCa patients.
Journal • Tumor Mutational Burden • IO biomarker
|
TMB (Tumor Mutational Burden) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
|
EZH2 underexpression
2years
High EZH2 Protein Expression Is a Poor Prognostic Predictor in IDH1 R132H-Negative Gliomas. (PubMed, Diagnostics (Basel))
High EZH2 immunoexpression is an unfavourable independent prognostic predictor of poor survival in gliomas. EZH2 analysis might therefore be of clinical value for risk stratification, especially in patients with IDH1 R132H-negative gliomas.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
|
IDH1 R132H • IDH1 R132 • EZH2 underexpression
2years
Analysis of the correlation between Zeste enhancer homolog 2 (EZH2) mRNA expression and the prognosis of mesothelioma patients and immune infiltration. (PubMed, Sci Rep)
EZH2, as a new prognostic biomarker for mesothelioma, contributes to elucidating how changes in the immune environment promote the development of mesothelioma. Further analysis, EZH2 may serve as a biological test to predict the prognosis of mesothelioma.
Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
|
EZH2 underexpression
over2years
IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer. (PubMed, Proc Natl Acad Sci U S A)
Notably, a combination of a novel histone methylation inhibitor with an HDAC inhibitor induces complete tumor eradication and long-term T cell memory in a HER2 BC mouse model. Our findings demonstrate an epigenetic regulatory mechanism suppressing the expression of the IFI16-CXCL10/11 signaling pathway that provides a survival advantage to HER2 BC to confer resistance to trastuzumab treatment.
Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IFI16 (Interferon Gamma Inducible Protein 16)
|
EZH2 underexpression
|
Herceptin (trastuzumab)